Quality of life in patients with rheumatoid arthritis receiving anti-В cell therapy (results of international studies and Russia registry)

1. <div><p>Quality of life assessment in clinical trials. Ed M.J.Staquet, Oxford University Press, Oxford, New York, Tokyo, 1998, 3</p><p>Quality of life and pharmacoeconomics in clinical trials. Ed. Spilker B., Philadelphia, New York Lippincott-Raven, 1996, 1259-1260.</p><p>Новик А.А, Ионова Т.Н. Руководство no исследованию качества жизни в медицине. М., ОЛМА-ПРЕСС, 2002, 314с.</p><p>Tugwell P., WellsG., MaetzelA. etal. Leflunomide Rheumatoid Arthritis Investigators Group.Clinical improvement as reflected in measures of functional and health-related quality of lifefollowing treatment with leflunomide compared with metotrexate in patients with rheumatoid arthritis: sensivity and relative efficiency to detect a treatment effect in twelve-month, placebo-controlled trial. Anhr. Rheum., 2000,43, 506-514.</p><p>Kosinski М., Zhao S.Z., Dedhiya S. et al. Determining minimally important changes in general and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Anhr. Rheum., 2000, 43, 7, 14781487.</p><p>Thuboo J.,Fong K. Y, Ng T.P. et a I Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore. J.Rheumatol., 1999, 26, 97-102</p><p>Strand V., Bombardier C., Naetzel A. et al. Use of minimum clinically important differences in evaluating patient responses to treatment of RA. Arthr. Rheum. (suppl.), 2001, 44, S187</p><p>Zhang Z.,Dridges S. L.J. Pathogenesis of rheumatoid arthritis: role of В lymphocytes. Rheum. Dis.Clin.North Am., 2001,27, 335-353</p><p>Сигидин Я.А. Лукина Г.В. Биологическая терапия в ревматологии.М., 2007, 179с</p><p>Leonardo M.J., Edwards J.C. W.,Camridge G.CIinicai outcome in 22 patients with rheumatoid arthritis treated with В lymphocyte depletion.Ann.Rheum.Dis., 2002, 46, 20292033</p><p>Насонов Е.Л. Перспективы применения моноклональных антител к В-лимфоцитам (ритуксимаб) при ревматоидном артрите. Клин.фармакол. терап., 2006, 1-5, 55-58</p><p>Emery P., Fleishmann R., Hlipowich-Sosnowska A.et al. for the DANCER study group. The Efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a phase lib randomized, double-blind, placebo-controlled dose-range trial. Arthr. Rheum., 2006, 54, 1390-1400</p><p>Cohen S. B.,Emery P.,Greenwald М. IV. et al. foe the REFLEX Trial Group. Rituximab for the rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of multicenter, randomized, double-blind, placebo-controlled , phase 111 trial evaluating primary efficacy and safety at twenty-four weeks. Arthr. Rheum., 2006, 54, 2793-2806.</p><p>Edwards J.C., Szczepanski L., Szczepanski J.et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med., 2004, 350, 25722581.</p><p>Kielhom A., Bombardieri S., Aultman R. et al. Rituximab improves health-related quality of life as measured by the SF-36: domain score results from the REFLEX study. Ann. Rheum. Dis., 2006, 65 (suppl. 2), 324</p><p>The Working Group on the Rituximab Consensus Statement. Ann. Rheum.Dis., 2007, 66, 143-150</p></div><br />